SCHEMBL2833992

SCHEMBL2833992

Cc1c(C(=O)O)c2ccccc2c(=O)n1C1CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.46
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 5/20 0.46
GAA P10253 1/20 0.46
ALOX15 P16050 1/20 0.46
NOTUM Q6P988 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
MAPT P10636 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ATM Q13315 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 2/20 0.39
POLB P06746 1/20 0.39
JAK2 O60674 1/20 0.38
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834061 0.94 GAA (0.50) MEN1ALDH1A1KMT2AGAAALOX15
SCHEMBL2834608 0.94 GAA (0.53) MEN1ALDH1A1KMT2AGAAALOX15
SCHEMBL2834010 0.93 GAA (0.56) MEN1ALDH1A1KMT2AGAAALOX15
SCHEMBL16344718 0.78 GAA (0.53) MEN1ALDH1A1KMT2AGAAALOX15
SCHEMBL7950658 0.77 TACR3 (0.48) MEN1ALDH1A1KMT2ASMN1; SMN2ATM
SCHEMBL27735261 0.77 GAA (0.55) MEN1ALDH1A1KMT2AGAAALOX15
SCHEMBL2831858 0.76 ATM (0.52) ALDH1A1GAAMAPTRAB9AATM
SCHEMBL2831253 0.74 ABCC1 (0.37) MEN1ALDH1A1KMT2AGAAMAPT
SCHEMBL2832896 0.74 KDM4E (0.47) MEN1ALDH1A1KMT2AGAAMAPT
SCHEMBL2834446 0.73 REN (0.41) NPC1RAB9AJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 MEN1 2461/4885ALDH1A1 2399/4885KMT2A 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.